Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

EBC Financial Group Partners with Shakti Regeneration Institute to Empower Marginalised Communities and Promote Indigenous Conservation Efforts 27-01-2025, 22:54

Global-e to Announce Financial Results for the Fourth 9-02-2023, 04:10